Recombinant viral vectors are disclosed that contain a nucleic acid encoding a Second Mitochondria-derived Activator of Caspases (Smac) protein inserted within an RNA virus genome, wherein the Smac protein specifically binds to at least a portion of an Inhibitor of Apoptosis Protein (IAP). Also disclosed are methods of treating cancer using the disclosed vectors.

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

The present application relates to viral sensitizers. More specifically, the present application relates to neddylation-activating enzyme inhibitors, as well as processes for their preparation and methods of using such compounds and compositions as viral sensitizers. The present application includes a method of increasing permissiveness of a cell to a virus or genetic material encoding components of the virus, comprising administering an effective amount of a neddylation-activating enzyme (NAE) inhibitor, or a salt, solvate and/or prodrug thereof, to the cell.